Living with Ulcerative Colitis in Japan: Biologic Persistence and Health-Care Resource Use.
Adherence
Health-care resource utilization
Persistence
Tumor necrosis factor inhibitor
Ulcerative colitis
Journal
Inflammatory intestinal diseases
ISSN: 2296-9365
Titre abrégé: Inflamm Intest Dis
Pays: Switzerland
ID NLM: 101677990
Informations de publication
Date de publication:
Dec 2021
Dec 2021
Historique:
received:
09
10
2020
accepted:
12
08
2021
entrez:
27
1
2022
pubmed:
28
1
2022
medline:
28
1
2022
Statut:
epublish
Résumé
The aim of the study was to improve understanding of adherence and persistence to biologics, and their association with health-care resource utilization (HCRU), in Japanese patients with moderate to severe ulcerative colitis (UC). Data were from Medical Data Vision, a secondary care administrative database. A retrospective, longitudinal cohort analysis was conducted of data from UC patients initiating biologic therapy between August 2013 and July 2016. Data collected for 2 years prior (baseline) and 2 years after (follow-up) the index date were evaluated. Patients completing biologic induction were identified, and adherence/persistence to biologic therapy calculated. HCRU, steroid, and immunosuppressant use during baseline and follow-up were assessed. Biologic switching during the follow-up was evaluated. Descriptive statistics (e.g., means and proportions) were obtained and inferential analyses (from Student's The analysis included 649 patients (adalimumab: 265; infliximab: 384). Biologic induction was completed by 80% of patients. Adherence to adalimumab was higher than that to infliximab ( Poor biologic persistence was associated with increased non-medication-associated HCRU. Effective treatments with high persistence levels and limited associated HCRU are needed in UC.
Identifiants
pubmed: 35083284
doi: 10.1159/000519123
pii: iid-0006-0186
pmc: PMC8739862
doi:
Types de publication
Journal Article
Langues
eng
Pagination
186-198Informations de copyright
Copyright © 2021 by S. Karger AG, Basel.
Déclaration de conflit d'intérêts
Joseph C. Cappelleri, Irene Modesto, Marco DiBonaventura, Timothy W. Smith, Sean Gardiner, and Irene Modesto are stockholders and employees of Pfizer Inc (who funded this study). At the time of conducting the study, Danielle Bargo and Takanori Tsuchiya were employees of Pfizer Inc. Theo Tritton and Tim Holbrook are employed by Adelphi Real World, which received funding from Pfizer in connection with the development of this manuscript. At the time of conducting the study, Daniel Bluff was an employee of Adelphi Real World.
Références
Patient Prefer Adherence. 2017 May 18;11:947-958
pubmed: 28572722
Inflamm Bowel Dis. 2019 Apr 11;25(5):945-954
pubmed: 30329067
Lancet. 2017 Apr 29;389(10080):1756-1770
pubmed: 27914657
Am J Manag Care. 2011 Jun;17(6):385-92
pubmed: 21756009
Am J Epidemiol. 2011 Mar 15;173(6):676-82
pubmed: 21330339
J Gastroenterol. 1995 Nov;30 Suppl 8:1-4
pubmed: 8563866
J Gastroenterol. 2019 Dec;54(12):1070-1077
pubmed: 31309327
Aliment Pharmacol Ther. 2009 Feb 1;29(3):247-57
pubmed: 18945258
J Med Econ. 2020 Apr;23(4):415-427
pubmed: 31858853
Gut. 2006 Jun;55(6):749-53
pubmed: 16698746
J Med Econ. 2011;14(4):397-402
pubmed: 21595522
Inflamm Bowel Dis. 2013 Jun;19(7):1528-33
pubmed: 23518810
Front Pharmacol. 2016 Jul 20;7:212
pubmed: 27489544
J Gastroenterol Hepatol. 2020 Feb;35(2):225-232
pubmed: 31397010
Dig Liver Dis. 2020 Aug;52(8):869-877
pubmed: 32563721
Mayo Clin Proc. 2014 Nov;89(11):1553-63
pubmed: 25199861
World J Gastroenterol. 2018 Dec 21;24(47):5322-5330
pubmed: 30598577
Intest Res. 2017 Oct;15(4):434-445
pubmed: 29142511
Dig Dis. 2019;37(4):266-283
pubmed: 30726845
Gut Liver. 2015 Jan;9(1):18-27
pubmed: 25547087
Ann Pharmacother. 2009 Jan;43(1):36-44
pubmed: 19126828
Biometrika. 1951 Jun;38(1-2):141-9
pubmed: 14848119
J Crohns Colitis. 2016 May;10(5):549-55
pubmed: 26738757
Value Health. 2017 Jun;20(6):752-761
pubmed: 28577692
J Crohns Colitis. 2017 Jul 1;11(7):769-784
pubmed: 28513805
F1000Res. 2018 Aug 7;7:
pubmed: 30135722
J Gastroenterol. 2009;44(7):659-65
pubmed: 19424654
Health Aff (Millwood). 2008 Jan-Feb;27(1):89-102
pubmed: 18180483
Dig Dis Sci. 2020 May;65(5):1436-1444
pubmed: 31677070
World J Gastroenterol. 2013 Jul 21;19(27):4344-50
pubmed: 23885145
Adv Ther. 2017 Nov;34(11):2422-2435
pubmed: 29039054
World J Gastroenterol. 2014 Jul 28;20(28):9458-67
pubmed: 25071340
Lancet. 2012 Nov 3;380(9853):1606-19
pubmed: 22914296
Am J Gastroenterol. 2019 Mar;114(3):384-413
pubmed: 30840605
J Gastroenterol. 2016 Mar;51(3):241-51
pubmed: 26162647
Am Health Drug Benefits. 2018 Jun;11(4):192-202
pubmed: 30464787
Therap Adv Gastroenterol. 2018 Jan 21;11:1756283X17750355
pubmed: 29383030
Patient Prefer Adherence. 2016 Aug 05;10:1509-19
pubmed: 27540283
PLoS One. 2015 Nov 11;10(11):e0141993
pubmed: 26560127
Lancet. 2018 Dec 23;390(10114):2769-2778
pubmed: 29050646
BMC Gastroenterol. 2012 Sep 24;12:132
pubmed: 23006789
J Gastroenterol. 2018 Mar;53(3):305-353
pubmed: 29429045